Table 3.
Trial name | Design | Type of therapy | Peptide | Route | Patient group | Immunomodulatory effects | Clinical efficacy† | Reference | |
---|---|---|---|---|---|---|---|---|---|
Diabetes | DiaPep277 | Phase II | Parenteral peptide | p277 (HSP60 437–460) | s.c. | New-onset T1D | Increased IL-10 production by T cells is associated with preservation of C-peptide up to 12–18 months | Lower need for exogenous insulin | Huurma, Clin Exp Immunol 2008 |
RA | Phase II | Oral peptide | DnaJP1 peptide (HSP40) | Oral | RA | Immune diviation from TNF-α to IL-10, peptide-induced FoxP3 expression on CD25bright cells | ACR20 and ACR50 score reduced | Koffeman, Arthritis Rheum 2009 |
ACR 20, ACR50, measurements of improvement in rheumatoid arthritis. T1D: type 1 diabetes; RA: rheumatoid arthritis; IL: interleukin; TNF: tumour necrosis factor.